Immunocore Holdings Plc ((IMCR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Immunocore Holdings Plc is conducting a Phase 2/3 study titled ‘Tebentafusp Regimen Versus Investigator’s Choice in Previously Treated Advanced Melanoma (TEBE-AM)’. The study aims to assess the efficacy and safety of tebentafusp-based treatments compared to investigator’s choice in patients with advanced non-ocular melanoma. This research is significant as it explores new treatment avenues for a challenging cancer type.
Intervention/Treatment: The study tests three interventions: Tebentafusp monotherapy, Tebentafusp combined with Pembrolizumab, and an investigator’s choice of therapy. Tebentafusp is a soluble gp100-specific T cell receptor with anti-CD3 scFV, designed to target melanoma cells.
Study Design: This is a randomized, parallel-assignment study with no masking, focusing on treatment as the primary purpose. Participants are allocated to one of the three treatment arms to evaluate the effectiveness of each intervention.
Study Timeline: The study began on August 26, 2022, and is currently recruiting. The last update was submitted on July 22, 2025. These dates are crucial as they indicate the study’s progress and ongoing nature.
Market Implications: The study’s progress could positively influence Immunocore’s stock performance by demonstrating potential breakthroughs in melanoma treatment. Investors may view this as a promising development, enhancing the company’s competitive position in the oncology sector.
The study is ongoing, with further details available on the ClinicalTrials portal.